Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study

In a randomized, placebo-controlled study, we studied the effects of 4 months' treatment with rosiglitazone on low-grade inflammation, liver function, lipid levels, and blood pressure in 30 overweight women with polycystic ovary syndrome. Rosiglitazone significantly decreased serum C-reactive p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Fertility and sterility Ročník 87; číslo 1; s. 202
Hlavní autoři: Rautio, Katrina, Tapanainen, Juha S, Ruokonen, Aimo, Morin-Papunen, Laure C
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.01.2007
Témata:
Adolescent
Adult
Female
Humans
Hypoglycemic Agents - administration & dosage
Inflammation - drug therapy
Liver Diseases - drug therapy
Obesity - drug therapy
Polycystic Ovary Syndrome - drug therapy
Thiazolidinediones - therapeutic use
Treatment Outcome
ISSN:1556-5653, 1556-5653
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In a randomized, placebo-controlled study, we studied the effects of 4 months' treatment with rosiglitazone on low-grade inflammation, liver function, lipid levels, and blood pressure in 30 overweight women with polycystic ovary syndrome. Rosiglitazone significantly decreased serum C-reactive protein levels, white blood cell count, and alanine aminotransferase enzyme activity but did not affect lipid or blood pressure levels. Placebo had no effect on any parameters.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1556-5653
1556-5653
DOI:10.1016/j.fertnstert.2006.05.061